Cited by 1,065HIV-related health complications and treatmentsLipid metabolism and disordersPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Carr, Andrew, Samaras, Katherine, Chisholm, Donald J, Cooper, David A·1998·The Lancet

DOI 10.1016/s0140-6736(98)03391-1

Open this paper in CoChat — free account

Abstract

HIV-1 protease-inhibitor treatments are associated with a syndrome of peripheral lipodystrophy, central adiposity, breast hypertrophy in women, hyperlipidaemia, and insulin resistance. The catalytic region of HIV-1 protease, to which protease inhibitors bind, has approximately 60% homology to regions within two proteins that regulate lipid metabolism: cytoplasmic retinoic-acid binding protein type 1 (CRABP-1) and low density lipoprotein-receptor-related protein (LRP). We hypothesise that protease inhibitors inhibit CRABP-1-modified, and cytochrome P450 3A-mediated synthesis of cis-9-retinoic acid, a key activator of the retinoid X receptor; and peroxisome proliferator activated receptor type gamma (PPAR-gamma) heterodimer, an adipocyte receptor that regulates peripheral adipocyte differentiation and apoptosis. Protease-inhibitor binding to LRP would impair hepatic chylomicron uptake and triglyceride clearance by the endothelial LRP-lipoprotein lipase complex. The resulting hyperlipidaemia contributes to central fat deposition (and in the breasts in the presence of oestrogen), insulin resistance, and, in susceptible individuals, type 2 diabetes. Understanding the syndrome's pathogenesis should lead to treatment strategies and to the design of protease inhibitors that do not cause this syndrome.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(98)03391-1

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,564
A decade of molecular biology of retinoic acid receptors
Chambon, P. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801176 · Cited by 2,889
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
FORMAN, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,857
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
Carr, A., Samaras, K., Burton, S., Law, M. G., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,364
Self-citation
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
Navia, M. A., Fitzgerald, P. M. D., McKeever, B. M., Leu, C., Heimbach, J. C., Herber, W. K., Sigal, I. S., Darke, P. L., & Springer, J. P. (1989) · Nature · doi:10.1038/337615a0 · Cited by 892
Visceral abdominal-fat accumulation associated with use of indinavir
Miller, K. D., Jones, E. C., Yanovski, J. A., Shankar, R., Feuerstein, I. M., & Falloon, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11518-5 · Cited by 697
The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein
Beisiegel†, U., Weber, W. T., Ihrke, G., Herz, J., & Stanley, K. K. (1989) · Nature · doi:10.1038/341162a0 · Cited by 680
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
Mukherjee, R., Davies, P. J., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., et al. (1997) · Nature · doi:10.1038/386407a0 · Cited by 601

Show all 24 references

Research works printed but not linked: 1

Despres, 1995, The insulin-resistance-dysipidemic syndrome: contributioin of visceral obesity and therapeutic implications, Int J Obesity, 19, S76

Sorted by citations

Items 401–500 of 1,000

Antiretroviral therapy and the human immunodeficiency virus – improved survival but at what cost?
Bradbury, R. A., & Samaras, K. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00760.x · Cited by 30
Self-citation
Lipodystrophy Syndrome in Children Infected with Human Immunodeficiency Virus
Wedekind, C. A., & Pugatch, D. L. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.9.861.34555 · Cited by 30
Estrogen Receptor-α Mediates Gender Differences in Atherosclerosis Induced by HIV Protease Inhibitors
Allred, K. F., Smart, E. J., & Wilson, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506046200 · Cited by 30
Striae formation in two HIV-positive persons receiving protease inhibitors
Darvay, A., Acland, K. M., Lynn, W. A., & Russell‐Jones, R. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70122-2 · Cited by 30
Effect of Highly Active Antiretroviral Therapy (HAART) and Hepatitis C Co-Infection on Hyperlipidemia in HIV-Infected Patients: A Retrospective Longitudinal Study
Andrea, P., Torti, C., Lina, T., Quirós-Roldán, E., Bertelli, D., Puoti, M., Cadeo, G. P., Sleiman, I., Tinelli, C., Carosi, G., et al. (2002) · HIV Clinical Trials · doi:10.1310/w024-qc4t-nxu0-tkyt · Cited by 30
Absence of Association Between Individual Thymidine Analogues or Nonnucleoside Analogues and Lipid Abnormalities in HIV-1–Infected Persons on Initial Therapy
Matthews, G. V., Moyle, G. J., Mandalia, S., Bower, M., Nelson, M. R., & Gazzard, B. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200008010-00002 · Cited by 30
Antiretroviral Prescribing Patterns in Treatment-Naïve Patients in the United States
McKinnell, J. A., Willig, J. H., Westfall, A. O., Nevin, C. R., Allison, J. J., Raper, J. L., Mugavero, M. J., & Saag, M. S. (2010) · AIDS Patient Care and STDs · doi:10.1089/apc.2009.0220 · Cited by 29
HIV Therapy—The State of ART
Looney, D. J., Ma, A., & Johns, S. T. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_440 · Cited by 29
“Glucose intolerance, hypertriglyceridemia, and hypercholesterolemia (Carr et al. 1881, 1998; Caron et al. 2001) can be induced by protease inhibitors, more so with first-generation PIs (e.g., indinavir) as well as the NRTIs 3TC and FTC (Dressman et al. 2003; Lenhard et al. 2000).”
Background
From lipodystrophy and insulin resistance to metabolic syndrome: HIV infection, treatment and aging
Capeau, J. (2007) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3281e66919 · Cited by 30
Reproducibility of DXA Estimations of Body Fat in HIV Lipodystrophy
Cavalcanti, R. B., Cheung, A. M., Raboud, J., & Walmsley, S. L. (2005) · Journal of Clinical Densitometry · doi:10.1385/jcd:8:3:293 · Cited by 29
How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?
Podzamczer, D., Ferrer, E., Martínez, E., del Río, L., Rosales, J., Curto, J., Ribera, E., Barrufet, P., Llibre, J. M., & Aranda, M. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2008.0264 · Cited by 29
“Among other factors, such as the effect of HIV infection itself,(4) protease inhibitors have been cited as participating in the development of lipohypertrophy, whereas thymidine analogs, through a mechanism of mitochondrial toxicity, seem to play an important role in lipoatrophy.(3,5) Lipodystrophy is usually defined…”
Lipid‐Lowering Efficacy and Safety After Switching to Atazanavir‐Ritonavir‐Based Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus
Nguyen, S., Eaton, S. A., Bain, A. M., Rahman, A. P., Payne, K. D., Bedimo, R. G., Herrington, J. D., Maclayton, D. O., Rodriguez‐Barradas, M. C., & Busti, A. J. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.3.323 · Cited by 29
Distribution of adipose tissue: Quantification and relationship with hepatic steatosis and vascular profiles of type 2 diabetic patients with metabolic syndrome
Illouz, F., Roulier, V., Rod, A., Gallois, Y., Pelle, C., Aubé, C., Rohmer, V., Ritz, P., & Ducluzeau, P. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.10.007 · Cited by 29
In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome
Mukhopadhyay, A. (2002) · Mitochondrion · doi:10.1016/s1567-7249(02)00042-9 · Cited by 29
LDL‐receptors expression in HIV‐infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy
Petit, J., Duong, M., Duvillard, L., Florentin, E., Portier, H., Lizard, G., Brun, J. M., Gambert, P., & Vergès, B. L. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00989.x · Cited by 29
Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus
Paparizos, V., Kyriakis, K. P., Botsis, C., Papastamopoulos, V., Hadjivassiliou, M., & Stavrianeas, N. G. (2000) · AIDS · doi:10.1097/00002030-200005050-00023 · Cited by 29
Effects of Chinese herbal medicine on hyperlipidemia and the risk of cardiovascular disease in HIV-infected patients in Taiwan
Tsai, F., Li, T., Cheng, C., Wu, Y., Lai, C., Ho, T., Liu, X., Tsang, H., Lin, T., Liao, C., et al. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.03.006 · Cited by 28
Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?
Bakasis, A., & Ανδρουτσάκος, Θ. (2021) · Cells · doi:10.3390/cells10051212 · Cited by 27
PXR-mediated organophorous flame retardant tricresyl phosphate effects on lipid homeostasis
Xiang, D., & Wang, Q. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.131250 · Cited by 29
Rapid progression of carotid lesions in HAART-treated HIV-1 patients
Maggi, P., Perilli, F., Lillo, A., Gargiulo, M., Ferraro, S., Grisorio, B., Ferrara, S. M., Carito, V., Bellacosa, C., Pastore, G., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.026 · Cited by 27
From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir
Curran, A., & Ribera, E. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.542145 · Cited by 28
“At first, these body changes were related to protease inhibitors (PI) [1,6].”
Background
An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro
McCoig, C. C., Dyke, G. V., Chou, C.-S., Picker, L. J., Ramilo, O., & Vitetta, E. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11482 · Cited by 28
HIV disease treatment in the era of HAART
Bonfanti, P., Capetti, A. F., & Rizzardini, G. (1999) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(99)80066-3 · Cited by 28
Anti‐retroviral therapy, insulin resistance and lipodystrophy
Gan, S. K., Samaras, K., Carr, A. D., & Chisholm, D. J. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00146.x · Cited by 28
Self-citation
Relationship Between Efficacy, Tolerance, and Plasma Drug Concentration of Ritonavir in Children With Advanced HIV Infection
Dumon, C., Solas, C., Thuret, I., Chambost, H., Lacarelle, B., Michel, G., & Durand, A. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00007 · Cited by 28
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience
Haubrich, R., Thompson, M., Schooley, R. T., Lang, W. G., IV, Stein, A. J., Séréni, D., van der Ende, M. E., Antunes, F., Richman, D., Pagano, G., et al. (1999) · AIDS · doi:10.1097/00002030-199912030-00013 · Cited by 28
Immunoreconstitution in Children Receiving Highly Active Antiretroviral Therapy Depends on the CD4 Cell Percentage at Baseline
Nikolic-Djokic, D., Essajee, S. M., Rigaud, M., Kaul, A., Chandwani, S., Hoover, W. D., Lawrence, R. M., Pollack, H. J., Sitnitskaya, Y., Hagmann, S. H. F., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/338567 · Cited by 28
Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia
Penzak, S. R., & Chuck, S. K. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.5 · Cited by 28
“In addition to a faster onset of PIH with ritonavir (compared to other PIs), data support the fact that both the prevalence and magnitude of lipid elevations is higher with ritonavir and that increases in triglyceride concentrations occur in a dose-dependent manner [3,4,12,16,21].”
Background
Protease inhibitors in HIV infection
Buss, N., & Duff, F. (1999) · BMJ · doi:10.1136/bmj.318.7176.122 · Cited by 28
Type 2 Diabetes Mellitus
Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 28
Toxic metabolic syndrome associated with HAART
Haugaard, S. B. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.3.429 · Cited by 27
“proposed in 1998 the hypothesis that protease inhibitors, by binding directly to the retinoic acid-binding domain of cytoplasmic retinoic acid-binding protein-1 (CRABP-1), and to the lipid-binding domain of LDL receptor-like protein (LRP), could impair proliferation and differentiation of adipose tissue [124].”
Background
Low Density Lipoprotein Apolipoprotein B Metabolism in Treatment-Naive HIV Patients and Patients on Antiretroviral Therapy
Umpleby, A. M., Das, S., Stolinski, M., Shojaee‐Moradie, F., Jackson, N. C., Jefferson, W., Crabtree, N., Nightingale, P., & Shahmanesh, M. (2005) · Antiviral Therapy · doi:10.1177/135965350501000508 · Cited by 27
“It has also been suggested that PIs may inhibit LRP since the catalytic region of HIV-1 protease, to which PIs bind, has approximately 60% homology to regions within LRP [30].”
Background
Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors
Olivé, A., Salavert, A., Manríquez, M., Clotet, B., & MORAGAS, A. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.12.749 · Cited by 27
Getting to the HAART of insulin resistance
Nolan, D. A., & Mallal, S. A. (2001) · AIDS · doi:10.1097/00002030-200110190-00018 · Cited by 27
“It must be borne in mind, however, that an alternative hypothesis also exists in which this temporal association is reversed, and a defect in post-prandial lipid metabolism leads to insulin resistance (as would be predicted if lipoproteinreceptor-related protein [20], or the acylation-stimulating protein pathway [21],…”
Background
HIV Lipodystrophy: Review of the Syndrome and Report of a Case Treated with Liposuction
Chastain, M. A., Chastain, J. B., & Coleman, W. P. (2001) · Dermatologic Surgery · doi:10.1046/j.1524-4725.2001.00359.x · Cited by 27
Cardiology and AIDS—HAART and the Consequences
Hoffmann, C., & JAEGER, H. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03908.x · Cited by 27
Hyperandrogenemia in Human Immunodeficiency Virus-Infected Women with the Lipodystrophy Syndrome1
Hadigan, C. M., Corcoran, C. P., Piecuch, S., Rodriguez, W. R., & Grinspoon, S. K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6923 · Cited by 27
Mitochondrial disorders
Schapira, A. H. V. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200010000-00004 · Cited by 27
Prevalence and factors associated with lipodystrophy in AIDS patients
Justina, L. B. D., Luiz, M. C., Maurici, R., & Schuelter‐Trevisol, F. (2014) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0240-2013 · Cited by 26
The Role of Caveolin 1 in HIV Infection and Pathogenesis
Mergia, A. (2017) · Viruses · doi:10.3390/v9060129 · Cited by 29
Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update
Hulgan, T. (2018) · Current HIV/AIDS Reports · doi:10.1007/s11904-018-0399-7 · Cited by 29
Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients.
Falasca, K., Manigrasso, M. R., Racciatti, D., Zingariello, P., Dalessandro, M., Ucciferri, C., Mancino, P., Marinopiccoli, M., Petrarca, C., Conti, P., et al. (2006) · PubMed · Cited by 26
Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV
Stürmer, M., Staszewski, S., & Doerr, H. W. (2007) · Antiviral Therapy · doi:10.1177/135965350701200514 · Cited by 26
The Insulin-Like Growth Factor System in Human Immunodeficiency Virus Infection: Relations to Immunological Parameters, Disease Progression, and Antiretroviral Therapy1
Helle, S. I., Ueland, T., Ekse, D., Frøland, S. S., Holly, J. M. P., Lønning, P. E., & Aukrust, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7135 · Cited by 26
Does Race Protect an Oriental Population From Developing Lipodystrophy in HIV-infected Individuals on HAART?
Chang, K. H., Kim, J., Song, Y. G., Hong, S., Lee, H. C., & Lim, S.-K. (2002) · Journal of Infection · doi:10.1053/jinf.2001.0924 · Cited by 26
Postprandial Lipoprotein Changes in Patients Taking Antiretroviral Therapy for HIV Infection
Stein, J. H., Merwood, M. A., Bellehumeur, J. L., McBride, P. E., Wiebe, D. A., & Sosman, J. M. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000152233.80082.9c · Cited by 26
A Marker Study of Therapeutically Transduced CD4+ Peripheral Blood Lymphocytes in HIV Discordant Identical Twins
Cooper, D. A., Penny, R., & Symonds, G. P. (1999) · Human Gene Therapy · doi:10.1089/10430349950018067 · Cited by 26
“These drugs now appear to cause very significant side effects, which may limit their use as a long-term therapeutic modality (Carr et al., 1988a, 1988b).”
Self-citation
Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy?
Zylberberg, H., Nalpas, B., Pol, S., Bréchot, C., & Viard, J. (2000) · AIDS · doi:10.1097/00002030-200009080-00025 · Cited by 26
Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy
García-Benayas, T., Blanco, F., de la Cruz, J. J., Soriano, V., & González‐Lahoz, J. (2003) · AIDS · doi:10.1097/00002030-200304110-00021 · Cited by 26
Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers
Barroso, S., Morén, C., Segura, À. G., Riba, N., Arnáiz, J. A., Manríquez, M., Santana, G., Blanco, J. L., Larousse, M., Loncà, M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216712 · Cited by 25
“However, we assumed that subclinical evidence of metabolic changes toxicity markers of antiretroviral drugs may become apparent after a few days of therapy [13,14,22].”
Background
Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era
Tsai, F., Cheng, C., Lai, C., Wu, Y., Ho, M., Wang, J.-H., Tien, N., Liu, X., Tsang, H., Lin, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22465 · Cited by 25
“The possible metabolic mechanism is probably due to the fact that PI may inhibit lipogenesis and adipocyte differentiation [37].”
Background
Injectable hyaluronic acid for the correction of HIV‐associated facial lipoatrophy
Denton, A. B., & Tsaparas, Y. F. (2007) · Otolaryngology · doi:10.1016/j.otohns.2006.11.049 · Cited by 25
Hyperlipidemia and inhibitors of HIV protease
Distler, O., Cooper, D. A., Deckelbaum, R. J., & Sturley, S. L. (2001) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200103000-00003 · Cited by 25
Self-citation
Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia
de Araújo, P. S. R., Ximenes, R. A. D. A., Lopes, C. F. C., Duarte, J. Y., da Silva, M. M., & Carneiro, E. M. (2007) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46652007000200002 · Cited by 25
Dietary Fat Alters HIV Protease Inhibitor–Induced Metabolic Changes in Mice
Lenhard, J. M., Croom, D. K., Weiel, J. E., Spaltenstein, A., Reynolds, D. J., & Furfine, E. S. (2000) · Journal of Nutrition · doi:10.1093/jn/130.9.2361 · Cited by 25
“For example, PI treatment decreased insulin levels in mice but the opposite may occur in humans (Carr et al. 1998a, Walli et al. 1998).”
BackgroundInfluential
Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease
Dumond, J., Boggetto, N., Schramm, H. J., Schramm, W., Takahashi, M., & Reboud‐Ravaux, M. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01622-2 · Cited by 25
Beyond Efficacy: The Impact of Combination Antiretroviral Therapy on Quality of Life
Sax, P. E., & Gathe, J. (2005) · AIDS Patient Care and STDs · doi:10.1089/apc.2005.19.563 · Cited by 25
Oral Glucose Tolerance and Insulin Sensitivity Are Unaffected by HIV Infection or Antiretroviral Therapy in Overweight Women
Danoff, A., Shi, Q., Justman, J. E., Mulligan, K. M., Hessol, N. A., Robison, E., Lu, D., Williams, T., Wichienkuer, P., & Anastos, K. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000147659.80642.5a · Cited by 25
The ophthalmologist and the global impact of the AIDS epidemic LV Edward Jackson Memorial Lecture
Belfort, R. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(99)00428-6 · Cited by 25
Longitudinal evolution of HIV‐1‐associated lipodystrophy is correlated to serum cortisol:DHEA ratio and IFN‐α
Christeff, N., de Truchis, P., Melchior, J., Perronne, C., & Gougeon, M. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.01068.x · Cited by 25
Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7α-hydroxylase mRNA levels
Williams, K., Rao, Y.-P., Natarajan, R., Pandak, W. M., & Hylemon, P. B. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.08.044 · Cited by 25
Intervention for Hyperlipidemia Associated With Protease Inhibitors
Melroe, N. H., Kopaczewski, J., Henry, K., & Huebsch, J. A. (1999) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/s1055-3290(06)60310-5 · Cited by 25
Epidural Lipomatosis Secondary to Indinavir in an HIV-Positive Patient
Cersosimo, M. G., Lasala, B., Folgar, S., & Micheli, F. E. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200201000-00009 · Cited by 25
THE MANAGEMENT OF THE CLINICAL COMPLICATIONS OF ANTIRETROVIRAL THERAPY
Stenzel, M. S., & Carpenter, C. C. J. (2000) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70137-9 · Cited by 25
Synergistic Antiadipogenic Effects of HIV Type 1 Protease Inhibitors with Tumor Necrosis Factor α : Suppression of Extracellular Insulin Action Mediated by Extracellular Matrix-Degrading Proteases
Mondal, D., LaRussa, V. F., & Agrawal, K. C. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/088922201753341988 · Cited by 24
“It is therefore likely that by having sequence homology with the LRP ligand-binding site, 17 the HIV PIs may putatively suppress the activity and clearance of fibrinolytic proteases, thus abrogating ECM integrity and adipogenic differentiation.”
Influential
Multiple circumscribed subcutaneous lipomas associated with use of human immunodeficiency virus protease inhibitors?
Bornhövd, E., Sakrauski, A., Brühl, H., Walli, R., Plewig, G., & Röcken, M. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03871.x · Cited by 25
Dyslipidaemia and cardiovascular risk in HIV infection
Kulasegaram, R., Peters, B. S., & Wierzbicki, A. S. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65529 · Cited by 25
Lipid Abnormalities During Saquinavir Soft-Gel???Based Highly Active Antiretroviral Therapy
Moyle, G. J., & Baldwin, C. (2006) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/01.pas.0000213299.11649.110 · Cited by 25
HIV and Global Cardiovascular Health
Wagle, A. A., Goerlich, E., Post, W. S., Woldu, B., Wu, K. C., & Hays, A. G. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01741-1 · Cited by 24
Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET
Sathekge, M. M., Maes, A., Kgomo, M., Stolz, A., Ankrah, A. O., & de Wiele, C. V. (2010) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3283359058 · Cited by 24
Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort
Vaughn, G. S., & Detels, R. (2007) · AIDS Care · doi:10.1080/09540120701203329 · Cited by 24
Insulin metabolism in human adipocytes from subcutaneous and visceral depots
Fawcett, J., Sang, H., Permana, P. A., Levy, J. L., & Duckworth, W. C. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.104 · Cited by 24
Severe acquired (secondary) high-density lipoprotein deficiency
Goldberg, R. B., & Mendez, A. J. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.02.003 · Cited by 24
HIV Protease Inhibitor Ritonavir Induces Lipoatrophy in Male Mice
Goetzman, E. S., Tian, L., Nagy, T. R., Gower, B. A., Schoeb, T. R., Elgavish, A., Acosta, E. P., Saag, M. S., & Wood, P. A. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203771881248 · Cited by 24
“Carr and colleagues 49,50 postulated that HIV protease inhibitors reduce the availability of cis -9-retinoic acid, the ligand for the retinoic acid receptor (RXR), which in turn limits the functionality of PPAR/RXR transcription factor heterodimers.”
Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells
Hamel, F. G., Fawcett, J., Tsui, B. T., Bennett, R. G., & Duckworth, W. C. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00546.x · Cited by 24
Nutrition in paediatric human immunodeficiency virus infection
Miller, T. L. (2000) · Proceedings of The Nutrition Society · doi:10.1017/s0029665100000185 · Cited by 24
Haemophilia 2002: emerging risks of treatment
Evatt, B. L., Farrugia, A., Shapiro, A. D., & Wilde, J. (2002) · Haemophilia · doi:10.1046/j.1365-2516.2002.00612.x · Cited by 24
Selective aspects of the insulin resistance syndrome
Corry, D. B., & Tuck, M. L. (2001) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200107000-00005 · Cited by 24
Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo
Shi, J., Cao, B., Zha, W., Wu, X., Liu, L., Xiao, W.-J., Gu, R., Sun, R., Yu, X., Zheng, T., et al. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.69 · Cited by 23
Proteinase Inhibitors: A Promising Drug Class for Treating Leishmaniasis
Pereira, B. A. S., Souza‐Silva, F., Silva-Almeida, M., de Souza, R. S., Júnior, L. F. G. D. O., Ribeiro-Guimarães, M. L., & Alves, C. R. (2014) · Current Drug Targets · doi:10.2174/1389450115666141016150007 · Cited by 23
Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review
Souza, S. J., Luzia, L. A., dos Santos, S. D. S., & Rondó, P. H. D. C. (2013) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(13)70454-5 · Cited by 23
Impact of Age on Markers of HIV-1 Disease
Pirrone, V., Libon, D. J., Sell, C., Lerner, C. A., Nonnemacher, M. R., & Wigdahl, B. L. (2012) · Future Virology · doi:10.2217/fvl.12.127 · Cited by 25
Protease inhibitor-related paronychia, ingrown toenails, desquamative cheilitis and cutaneous xerosis
García-Silva, J., Almagro, M., Juega, J., Peña, C., López‐Calvo, S., del Pozo, J., & Fonseca, E. (2000) · AIDS · doi:10.1097/00002030-200006160-00035 · Cited by 23
CD38+CD8+ T Cells as a Marker of Poor Response to Therapy in HIV-Infected Individuals
Viganò, M., Saresella, M., Villa, M. L., Ferrante, P., & Clerici, M. (2000) · KARGER eBooks · doi:10.1159/000058770 · Cited by 23
The molecular basis of genetic lipodystrophies
Bhayana, S., & Hegele, R. A. (2002) · Clinical Biochemistry · doi:10.1016/s0009-9120(02)00297-7 · Cited by 23
Alteraciones lipídicas y riesgo cardiovascular asociado a la terapia antirretroviral
Masiá, M., Bernal, E., & Gutiérrez, F. (2006) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13095376 · Cited by 23
Changes in Metabolic Parameters and Body Shape After Replacement of Protease Inhibitor With Efavirenz in Virologically Controlled HIV-1–Positive Persons: Single-Arm Observational Cohort
Moyle, G. J., Baldwin, C., Mandalia, S., Comitis, S., Burn, P. R., & Gazzard, B. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200112010-00016 · Cited by 23
Lipoatrophy, Fat Accumulation, and Mixed Syndrome in Protease Inhibitor???Naive HIV-Infected Patients
Polo, R., Verdejo, J., Martinez-Rodriguez, S., Madrigal, P., & González‐Muñoz, M. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200011010-00014 · Cited by 23
Altered Fat Distribution in HIV-Positive Men on Nucleoside Analog Reverse Transcriptase Inhibitor Therapy
Mulligan, K. M., Tai, V., Algren, H. A., Abrams, D. I., Leiser, R. J., Lo, J. C.-M., & Schambelan, M. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200104150-00006 · Cited by 23
Associations between antiretroviral use and subclinical coronary atherosclerosis
Thomas, G. P., Li, X., Post, W. S., Jacobson, L. P., Witt, M. D., Brown, T. T., Kingsley, L., Phair, J., & Palella, F. J. (2016) · AIDS · doi:10.1097/qad.0000000000001220 · Cited by 22
Lipodystrophy, Insulin Resistance, Diabetes Mellitus, Dyslipidemia, and Cardiovascular Disease in Human Immunodeficiency Virus Infection
Tanwani, L. K., & Mokshagundam, S. L. (2003) · Southern Medical Journal · doi:10.1097/01.smj.0000051731.69719.2e · Cited by 22
Antiretroviral therapy 2006: Pharmacology, applications, and special situations
Samuel, R., Bettiker, R. L., & Suh, B. (2006) · Archives of Pharmacal Research · doi:10.1007/bf02969415 · Cited by 22
Cardiovascular Disease Risk Factors in HIV‐Infected Patients in the HAART Era
Galli, M., Ridolfo, A. L., & Gervasoni, C. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03913.x · Cited by 22
Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status
Malavazi, I., Abrão, E. P., Mikawa, A. Y., Landgraf, V. O., & da Costa, P. I. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.089 · Cited by 22
“PIs can also inhibit the LRP nonspecifically by competing in the same manner as PIs do at the catalytic region of HIV-1 protease (3, 5).”
Background
Reduced Reactive Hyperemia in HIV-Infected Patients
Monsuez, J.-J., Dufaux, J., Vittecoq, D., & Vicaut, É. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200012150-00009 · Cited by 22
Effect of antiretroviral agents on carbohydrate metabolism in HIV‐1 infected pregnant women
Beitune, P. E., Duarte, G. G., Foss, M. C., Montenegro, R. M., Spara, P., Quintana, S. M., Figueiró-Filho, E. A., da Costa, A. G., & Filho, F. M. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.576 · Cited by 22
Clinical characteristics and mid‐term prognosis of acute coronary syndrome in HIV‐infected patients on antiretroviral therapy
Boccara, F., Éderhy, S., Janower, S., Benyounes, N., Odi, G., & Cohen, A. A. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00283.x · Cited by 22
Effects of Growth Hormone-Releasing Hormone on Bone Turnover in Human Immunodeficiency Virus-Infected Men with Fat Accumulation
Koutkia, P., Hron, B. M., Breu, J. J., & Grinspoon, S. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1466 · Cited by 22
Probing the role of interfacial residues in a dimerization inhibitor of HIV-1 protease
Shultz, M. D., & Chmielewski, J. A. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00400-x · Cited by 22
Immunomodulators as adjunctive therapy for HIV-1 infection
Pett, S. L., & Emery, S. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(01)00201-3 · Cited by 22

Authors: Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A.
Affiliations: UNSW Sydney (AU)
Garvan Institute of Medical Research (AU)
Corresponding author: Carr, Andrew
ORCID: Samaras, Katherine
Chisholm, Donald J
Venue: The Lancet
Publisher: Elsevier BV
Published: 1998-06
Volume: 351
Issue: 9119
Pages: 1881-1883
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(98)03391-1
OpenAlex: W2171030070
Cited by: 1,065
References: 24
Citations by year: 2026: 2 · 2025: 3 · 2024: 12 · 2023: 2 · 2022: 12 · 2021: 7 · 2020: 10 · 2019: 16 · 2018: 15 · 2017: 18 · 2016: 15 · 2015: 18 · 2014: 17 · 2013: 30 · 2012: 23
FWCI: 143.69
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council
National Medical Research Council
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords: HIV-1 protease inhibitors, hyperlipidemia, insulin resistance, abdominal obesity, breast hypertrophy, LRP, retinoic acid synthesis, retinoid X receptor, PPARγ, adipogenesis, adipocyte apoptosis, lipoprotein lipase, type 2 diabetes
MeSH terms: Cytochrome P-450 Enzyme System, Diabetes Mellitus, Type 2, Female, Humans, Hyperlipidemias, Insulin Resistance, Lipodystrophy, Obesity, Receptors, Immunologic, HIV Protease Inhibitors, Sequence Homology, Amino Acid, Receptors, Retinoic Acid, Low Density Lipoprotein Receptor-Related Protein-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks